Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Equillium, Inc.EQ · Entity 6560 | Principal Accounting Officer | May 28, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Equillium, Inc.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-05-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-28 · Exercise / conversion · Acquired 65,000 · Balance 65,000 Row 2 · 2026-05-28 · Sale · Disposed 65,000 · Balance 0 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 10, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.95 to $2.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.79 · Expires 2029-01-30 | Direct | 0 |
Reported balance
After 2026-05-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-28 · Exercise / conversion · Disposed 65,000 · Balance 0 F3: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 10, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.95 to $2.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2026 Filed May 29, 2026 22:28 UTC | Equillium, Inc. EQ · Entity 6560 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0002012180-26-000002 · form4-05292026_100546.xml · derivative · entry 3 Tom Penny · CIK 0002012180 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,000 shares Expires 2029-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| May 28, 2026 Filed May 29, 2026 22:28 UTC | Equillium, Inc. EQ · Entity 6560 | SaleCommon Stock | 65,000 | $2.95 | $191,750.00 |
DisclosureSEC source: 0002012180-26-000002 · form4-05292026_100546.xml · nonDerivative · entry 2 Tom Penny · CIK 0002012180 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 10, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.95 to $2.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 28, 2026 Filed May 29, 2026 22:28 UTC | Equillium, Inc. EQ · Entity 6560 | Exercise / conversionCommon Stock | 65,000 | $0.79 | $51,025.00 |
DisclosureSEC source: 0002012180-26-000002 · form4-05292026_100546.xml · nonDerivative · entry 1 Tom Penny · CIK 0002012180 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2026 Filed Jan 9, 2026 22:37 UTC | Equillium, Inc. EQ · Entity 6560 | SaleCommon Stock | 6,533 | $1.29 | $8,427.57 |
DisclosureSEC source: 0002012180-26-000001 · form4-01092026_100107.xml · nonDerivative · entry 1 Tom Penny · CIK 0002012180 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 10, 2025. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 22:37 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 450,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0002012180-26-000001 · form4-01092026_100107.xml · derivative · entry 2 Tom Penny · CIK 0002012180 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2036-01-06 F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| August 29, 2025 Filed Sep 3, 2025 21:02 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 525,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-25-023569 · form4-09032025_090942.xml · derivative · entry 1 Tom Penny · CIK 0002012180 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 525,000 Underlying: Common Stock · 525,000 shares Expires 2035-08-28 F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:31 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $1.06 | Not disclosed |
DisclosureSEC source: 0001415889-25-004755 · form4-02202025_120220.xml · derivative · entry 12 Tom Penny · CIK 0002012180 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2033-01-02 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:31 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004755 · form4-02202025_120220.xml · derivative · entry 11 Tom Penny · CIK 0002012180 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-01-02 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:31 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 40,000 | Not disclosed Strike: $2.52 | Not disclosed |
DisclosureSEC source: 0001415889-25-004755 · form4-02202025_120220.xml · derivative · entry 10 Tom Penny · CIK 0002012180 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2032-05-01 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:31 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004755 · form4-02202025_120220.xml · derivative · entry 9 Tom Penny · CIK 0002012180 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-05-01 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:31 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 60,000 | Not disclosed Strike: $3.86 | Not disclosed |
DisclosureSEC source: 0001415889-25-004755 · form4-02202025_120220.xml · derivative · entry 8 Tom Penny · CIK 0002012180 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2032-01-18 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:31 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 60,000 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004755 · form4-02202025_120220.xml · derivative · entry 7 Tom Penny · CIK 0002012180 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-01-18 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:31 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 40,000 | Not disclosed Strike: $5.03 | Not disclosed |
DisclosureSEC source: 0001415889-25-004755 · form4-02202025_120220.xml · derivative · entry 6 Tom Penny · CIK 0002012180 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2031-01-03 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:31 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004755 · form4-02202025_120220.xml · derivative · entry 5 Tom Penny · CIK 0002012180 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-01-03 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:31 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 45,000 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001415889-25-004755 · form4-02202025_120220.xml · derivative · entry 4 Tom Penny · CIK 0002012180 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2029-12-09 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:31 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 45,000 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004755 · form4-02202025_120220.xml · derivative · entry 3 Tom Penny · CIK 0002012180 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-12-09 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:31 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 65,000 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001415889-25-004755 · form4-02202025_120220.xml · derivative · entry 2 Tom Penny · CIK 0002012180 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,000 shares Expires 2029-01-30 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:31 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 65,000 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004755 · form4-02202025_120220.xml · derivative · entry 1 Tom Penny · CIK 0002012180 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2029-01-30 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:26 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001415889-25-000858 · form4-01062025_110145.xml · derivative · entry 1 Tom Penny · CIK 0002012180 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2035-01-01 F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 20:15 UTC | Equillium, Inc. EQ · Entity 6560 | SaleCommon Stock | 2,835 | $1.25 | $3,543.75 |
DisclosureSEC source: 0001415889-24-025695 · form4-10292024_041001.xml · nonDerivative · entry 2 Tom Penny · CIK 0002012180 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,533 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 14, 2024. Read SEC document |
| October 25, 2024 Filed Oct 29, 2024 20:15 UTC | Equillium, Inc. EQ · Entity 6560 | SaleCommon Stock | 683 | $1.25 | $853.75 |
DisclosureSEC source: 0001415889-24-025695 · form4-10292024_041001.xml · nonDerivative · entry 1 Tom Penny · CIK 0002012180 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,368 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 14, 2024. Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 22:14 UTC | Equillium, Inc. EQ · Entity 6560 | SaleCommon Stock | 38,806 | $0.85 | $32,985.10 |
DisclosureSEC source: 0001415889-24-023546 · form4-09172024_100911.xml · nonDerivative · entry 1 Tom Penny · CIK 0002012180 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,051 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 14, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.83 to $0.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 15,000 shares acquired by the reporting person under the Issuer's 2018 Employee Stock Purchase Plan on June 10, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.